467 related articles for article (PubMed ID: 17408955)
1. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
[TBL] [Abstract][Full Text] [Related]
2. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
[TBL] [Abstract][Full Text] [Related]
3. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.
Yavich L; Oksman M; Tanila H; Kerokoski P; Hiltunen M; van Groen T; Puoliväli J; Männistö PT; García-Horsman A; MacDonald E; Beyreuther K; Hartmann T; Jäkälä P
Neurobiol Dis; 2005 Nov; 20(2):303-13. PubMed ID: 16242637
[TBL] [Abstract][Full Text] [Related]
4. Tau protein: relevance to Parkinson's disease.
Lei P; Ayton S; Finkelstein DI; Adlard PA; Masters CL; Bush AI
Int J Biochem Cell Biol; 2010 Nov; 42(11):1775-8. PubMed ID: 20678581
[TBL] [Abstract][Full Text] [Related]
5. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
6. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
9. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.
Fulga TA; Elson-Schwab I; Khurana V; Steinhilb ML; Spires TL; Hyman BT; Feany MB
Nat Cell Biol; 2007 Feb; 9(2):139-48. PubMed ID: 17187063
[TBL] [Abstract][Full Text] [Related]
10. Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers.
Danzer KM; Schnack C; Sutcliffe A; Hengerer B; Gillardon F
J Neurochem; 2007 Dec; 103(6):2401-7. PubMed ID: 17883396
[TBL] [Abstract][Full Text] [Related]
11. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.
Frasier M; Walzer M; McCarthy L; Magnuson D; Lee JM; Haas C; Kahle P; Wolozin B
Exp Neurol; 2005 Apr; 192(2):274-87. PubMed ID: 15755545
[TBL] [Abstract][Full Text] [Related]
12. Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation.
Benussi L; Ghidoni R; Paterlini A; Nicosia F; Alberici AC; Signorini S; Barbiero L; Binetti G
Exp Cell Res; 2005 Aug; 308(1):78-84. PubMed ID: 15904919
[TBL] [Abstract][Full Text] [Related]
13. Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies.
Shao CY; Crary JF; Rao C; Sacktor TC; Mirra SS
J Neuropathol Exp Neurol; 2006 Apr; 65(4):327-35. PubMed ID: 16691114
[TBL] [Abstract][Full Text] [Related]
14. Live cell imaging of cytoskeletal dynamics in neurons using fluorescence photoactivation.
Gauthier A; Brandt R
Biol Chem; 2010 Jun; 391(6):639-43. PubMed ID: 20370315
[TBL] [Abstract][Full Text] [Related]
15. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B
Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains.
Stöckl M; Fischer P; Wanker E; Herrmann A
J Mol Biol; 2008 Feb; 375(5):1394-404. PubMed ID: 18082181
[TBL] [Abstract][Full Text] [Related]
17. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
[TBL] [Abstract][Full Text] [Related]
18. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells.
Furukawa K; Matsuzaki-Kobayashi M; Hasegawa T; Kikuchi A; Sugeno N; Itoyama Y; Wang Y; Yao PJ; Bushlin I; Takeda A
J Neurochem; 2006 May; 97(4):1071-7. PubMed ID: 16606366
[TBL] [Abstract][Full Text] [Related]
19. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
20. Initiation and synergistic fibrillization of tau and alpha-synuclein.
Giasson BI; Forman MS; Higuchi M; Golbe LI; Graves CL; Kotzbauer PT; Trojanowski JQ; Lee VM
Science; 2003 Apr; 300(5619):636-40. PubMed ID: 12714745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
